FBXO24: A promising drug target and biomarker for cancer (G26261)

Target Name: FBXO24

NCBI ID: G26261

FBXO24

FBXO24: A promising drug target and biomarker for cancer

Introduction

FBXO24 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a member of the F-box only protein (FBP) family, which are known for their unique structural features that allow them to interact with various signaling molecules. One of the most interesting aspects of FBXO24 is its potential as a drug target or biomarker for cancer. In this article, we will explore the biology of FBXO24 and its potential as a drug target for cancer.

FBXO24 biology and localization

FBXO24 is a 24 kDa protein that is expressed in various tissues of the body. It is highly expressed in the brain, with low levels in the heart, liver, and muscle. FBXO24 is also known to be involved in the regulation of cellular processes that are important for brain development and function, such as cell adhesion, migration, and survival.

FBXO24 is localized to the endoplasmic reticulum (ER) and nuclear speckles, which are the sites of protein synthesis and modification. . It is also known to be involved in the regulation of protein synthesis and degradation, as well as in the formation of the nuclear envelope.

FBXO24 as a drug target

FBXO24 has been identified as a potential drug target for cancer due to its unique structure and the various functions that it is involved in. One of the main reasons for its potential as a drug target is its ability to interact with various signaling molecules, including tyrosine kinases, poly (ADP-ribose) polymerase (PARP), and microtubules.

FBXO24 has been shown to play a role in the regulation of cellular processes that are important for cancer growth and progression. For example, studies have shown that FBXO24 can inhibit the tyrosine kinase activity of PD-L1, a protein that is involved in immune evasion and cancer cell survival. Additionally, FBXO24 has been shown to play a role in the regulation of PARP activity, which is involved in the repair of DNA damage.

FBXO24 has also been shown to be involved in the regulation of microtubule dynamics, which are important for cell division and migration. This suggests that FBXO24 may be a useful target for cancer therapies that target these processes.

FBXO24 as a biomarker

In addition to its potential as a drug target, FBXO24 has also been shown to be a useful biomarker for cancer. Its high expression in the brain makes it an attractive target for diagnostic tests that are used to detect brain tumors. Additionally, FBXO24 has been shown to be involved in the regulation of cellular processes that are important for cancer growth and progression, which makes it an attractive target for biomarkers that can be used to track the progression of cancer.

FBXO24 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. This suggests that FBXO24 may be a useful target for cancer therapies that target angiogenesis.

Conclusion

In conclusion, FBXO24 is a protein that has the potential to be a drug target or biomarker for cancer. Its unique structure and the various functions that it is involved in make it an attractive target for both drug and biomarker development. Further research is needed to fully understand the biology of FBXO24 and its potential as a drug

Protein Name: F-box Protein 24

Functions: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex

The "FBXO24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets